Achaogen
About Us
Company Overview
Our Culture
Management Team
Board of Directors
Our Focus
Overview
MDR Gram-Negative Infections
Our Science
Pipeline
Pipeline Overview
Plazomicin
C-Scape
LpxC Inhibitor Program
Monoclonal Antibody Program
Additional Gram-Negative Programs
Scientific Publications
Investors
Investor Overview
Press Releases
Events & Presentations
Corporate Governance
Financials & Filings
Stock Information
Contact Us
Careers
Overview
Values
Positions Available
Postdoctoral Program
Benefits
Fellowship
Contact Us
Contact Information
Medical Information
About Us
/
Company Overview
Our Culture
Management Team
Board of Directors
Our Focus
/
Overview
MDR Gram-Negative Infections
Our Science
Pipeline
/
Pipeline Overview
Plazomicin
C-Scape
LpxC Inhibitor Program
Monoclonal Antibody Program
Additional Gram-Negative Programs
Scientific Publications
Investors
/
Investor Overview
Press Releases
Events & Presentations
Corporate Governance
Financials & Filings
Stock Information
Contact Us
Careers
/
Overview
Values
Positions Available
Postdoctoral Program
Benefits
Fellowship
Contact Us
/
Contact Information
Medical Information
/
Media
About Us
/
Company Overview
Our Culture
Management Team
Board of Directors
Our Focus
/
Overview
MDR Gram-Negative Infections
Our Science
Pipeline
/
Pipeline Overview
Plazomicin
C-Scape
LpxC Inhibitor Program
Monoclonal Antibody Program
Additional Gram-Negative Programs
Scientific Publications
Investors
/
Investor Overview
Press Releases
Events & Presentations
Corporate Governance
Financials & Filings
Stock Information
Contact Us
Careers
/
Overview
Values
Positions Available
Postdoctoral Program
Benefits
Fellowship
Contact Us
/
Contact Information
Medical Information
/
Media Archive
Press Releases
Scientific Publications
See more press releases
Media
Plazomicin (PLZ) Associated with Improved Survival and Safety Compared to Colistin (CST) in Serious Carbapenem-Resistant Enterobacteriaceae (CRE) Infections: Results of the CARE Study
about 3 months ago
Evaluating Once-Daily Plazomicin versus Meropenem for the Treatment of Complicated Urinary Tract Infection (cUTI) and Acute Pyelonephritis (AP): Results from a Phase 3 Study (EPIC)
about 3 months ago
Aminoglycoside-Resistant Genes among 2014-2015 US Carbapenem-Resistant Enterobacteriaceae Isolates and Activity of Plazomicin against Characterized Isolates
about 3 months ago
See more scientific publications
